Dyne Therapeutics
Develops targeted genetic medicines for neuromuscular diseases through its FORCE delivery platform.
$25.07
After-hours close−0.01 (−0.04%)
At close$25.08(−3.87%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 104.25%Insiders 2.76%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 186.75M · Float 152.33M · 81.6% free float
Institutions13F, as of Jun 30, 2026
254 holders · 194.68M shares · 50 new positions · 141 increased · 74 reduced · 32 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 30.91M | 16.55% | +126.5K | Aug 14, 2026 |
| BlackRock, Inc. | 12.40M | 6.64% | +704.5K | Aug 7, 2026 |
| Jupiter Topco LLC | 12.00M | 6.42% | +12.00Mnew | Aug 14, 2026 |
| FMR LLC | 11.21M | 6.00% | +2.30M | Aug 13, 2026 |
| State Street Corp | 7.46M | 3.99% | +804.5K | Aug 7, 2026 |
| Orbis Allan Gray Ltd | 7.01M | 3.75% | +244.3K | Aug 14, 2026 |
| Atlas Venture Life Science Advisors, LLC | 6.80M | 3.64% | −2.33M | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.31M | 3.38% | −94.1K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.70% | 30.79M | 13G | May 15, 2026 ↗ |
| Janus Henderson Group PLC | 8.30% | 13.65M | 13G | May 15, 2026 ↗ |
| Ein #incl. Janus Henderson Group plc | 6.80% | 6.81M | Nov 14, 2024 ↗ | |
| BlackRock, Inc. | 5.80% | 6.58M | 13G | Apr 17, 2025 ↗ |
| FMR LLC | 5.40% | 8.91M | 13G | May 6, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Dirk Kersten | director | 3.59M | 1.92% | Jul 29, 2026 |
| Jason P. Rhodes | director | 428.9K | 0.23% | Aug 17, 2026 |
| John Cox | director, officer: CEO & President | 363.2K | 0.19% | Aug 17, 2026 |
| Oxana Beskrovnaya | officer: Chief Scientific Officer | 195.8K | 0.10% | Mar 13, 2025 |
| Douglas Kerr | officer: Chief Medical Officer | 167.6K | 0.09% | Aug 17, 2026 |
| Johanna Friedl-Naderer | officer: Chief Commercial Officer | 154.0K | 0.08% | Aug 17, 2026 |
| Richard William Scalzo | officer: SVP, Head of Finance & Admin. | 122.3K | 0.07% | Mar 13, 2025 |
| Erick Lucera | officer: Chief Financial Officer | 119.8K | 0.06% | Aug 17, 2026 |
| Brian S. Posner | director | 24.5K | 0.01% | Jun 9, 2026 |
12 ten-percent owners hold 64.88M shares by Form 4, outside the officers-and-directors figure above · 17 people have not refiled in the last 18 months (3.60M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 13, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 426,412 | $26.20 | 751,411 |
| Aug 14, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 2,160,516 | $25.00 | 428,946 |
| Aug 13, 2026 | Johanna Friedl-Nadererofficer: Chief Commercial Officer | Sale | 226 | $26.28 | 153,982 |
| Aug 13, 2026 | Erick Luceraofficer: Chief Financial Officer | Sale | 1,797 | $26.28 | 119,766 |
| Aug 13, 2026 | John Coxdirector, officer: CEO & President | Sale | 4,986 | $26.28 | 363,165 |
| Aug 13, 2026 | Douglas Kerrofficer: Chief Medical Officer | Sale | 1,556 | $26.28 | 167,599 |
| Jul 27, 2026 | Dirk Kerstendirector | Sale · 2 lots | 261,460 | $25.51 | 3,586,796 |
| Jul 7, 2026 | Jason P. Rhodesdirector | Sale · 7 lots | 297,211 | $23.26 | 2,962 |
| Jul 6, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 480,240 | $22.79 | 875,912 |
| Jun 29, 2026 | Jason P. Rhodesdirector | Sale · 3 lots | 195,427 | $21.14 | 975,931 |
CongressHouse and Senate disclosures
Not reported.